ID   EB66
AC   CVCL_G703
DR   Wikidata; Q54831755
RX   Patent=US9260694;
RX   PubMed=20562528;
RX   PubMed=21502045;
RX   PubMed=25903999;
RX   PubMed=26409141;
CC   Group: Bird cell line.
CC   Group: Patented cell line.
CC   Group: Serum/protein free medium cell line.
CC   Group: Vaccine production cell line.
CC   From: Valneva SE; Saint-Herblain; France.
CC   Derived from site: In situ; Blastocyst; UBERON=UBERON_0000358.
CC   Cell type: Embryonic stem cell; CL=CL_0002322.
CC   Breed/subspecies: GL30.
OX   NCBI_TaxID=8839; ! Anas platyrhynchos (Mallard)
SX   Male
AG   Blastocyst stage
CA   Embryonic stem cell
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 16
RX   Patent=US9260694;
RA   Guehenneux F., Moreau K., Esnault M., Mehtali M.;
RT   "Generation of duck cell lines.";
RL   Patent number US9260694, 16-Feb-2016.
RX   PubMed=20562528;
RA   Olivier S., Jacoby M., Brillon C., Bouletreau S., Mollet T.,
RA   Nerriere O., Angel A., Danet S., Souttou B., Guehenneux F.,
RA   Gauthier L., Berthome M., Vie H., Beltraminelli N., Mehtali M.;
RT   "EB66 cell line, a duck embryonic stem cell-derived substrate for the
RT   industrial production of therapeutic monoclonal antibodies with
RT   enhanced ADCC activity.";
RL   MAbs 2:405-415(2010).
RX   PubMed=21502045;
RA   Brown S.W., Mehtali M.;
RT   "The avian EB66(R) cell line, application to vaccines, and therapeutic
RT   protein production.";
RL   PDA J. Pharm. Sci. Technol. 64:419-425(2010).
RX   PubMed=25903999; DOI=10.1002/biot.201400388;
RA   Genzel Y.;
RT   "Designing cell lines for viral vaccine production: where do we
RT   stand?";
RL   Biotechnol. J. 10:728-740(2015).
RX   PubMed=26409141; DOI=10.1016/j.vaccine.2015.09.022;
RA   Naruse T., Fukuda T., Tanabe T., Ichikawa M., Oda Y., Tochihara S.,
RA   Kimachi K., Kino Y., Ueda K.;
RT   "A clinical phase I study of an EB66 cell-derived H5N1 pandemic
RT   vaccine adjuvanted with AS03.";
RL   Vaccine 33:6078-6084(2015).